Vect-Horus S.A.S.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Vect-Horus S.A.S. - overview
Established
2005
Location
Marseille, -, France
Primary Industry
Biotechnology
About
Vect-Horus S. A. S. is a biotechnology company specializing in advanced drug delivery systems that enhance therapeutic efficacy, particularly across the blood-brain barrier, targeting neurological disorders.
Founded in 2005 in Marseille, France, Vect-Horus focuses on innovative drug delivery solutions. The company has successfully completed 12 deals, with its most recent funding round occurring on February 20, 2023, raising EUR 4. 04 mn from investors including Alpha Centauri and CAAP Creation. The company's total amount raised to date is EUR 4.
04 mn, with a current valuation of EUR 57. 097 mn. Vect-Horus specializes in advanced drug delivery systems, focusing on technology that facilitates the passage of therapeutic agents across the blood-brain barrier. Their proprietary platforms enhance the efficacy of central nervous system therapies and address challenges related to neurological disorders.
The company serves pharmaceutical companies, research institutions, and healthcare providers across Europe and North America, emphasizing mRNA-based therapeutics and partnerships in the biotechnology sector. In 2023, Vect-Horus reported a revenue of EUR 25,032,716. 70, with an EBITDA of EUR 18,274,285. The company's revenue is generated through strategic partnerships, collaborations with pharmaceutical firms, and possible licensing agreements, ensuring access to its proprietary technologies.
Vect-Horus plans to leverage the EUR 4. 04 mn raised in February 2023 to advance its drug delivery systems and expand its market presence. The company seeks to launch new products aimed at enhancing the treatment of central nervous system disorders and is targeting growth in additional regions beyond its current markets in Europe and North America.
Current Investors
Banque Populaire Provencale et Corse, Crédit Agricole Alpes Provence, Financière Tuileries Co-Invest
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Bioinformatics, Pharmaceutical Research & Development
Website
www.vect-horus.com
Verticals
Manufacturing
Company Stage
Late Stage
Total Amount Raised
Subscriber access only
Vect-Horus S.A.S. - timeline of key events
Vect-Horus S.A.S. - financials
| Fiscal Year Ended | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 16,500 | 2,100 | 649,230 | 913,350 | 285,758 | 720,074 | - | - | - |
| % Revenue Growth (YoY) | - | (87.3%) | 30815.7% | 40.7% | (68.7%) | 152.0% | - | - | - |
| EBITDA (USD) | (2,012,983) | (2,337,078) | (1,749,700) | (2,518,368) | (3,226,860) | (3,456,595) | - | - | - |
| Operating Income (USD) | (2,033,445) | (2,357,016) | (1,770,822) | (2,543,710) | (3,271,088) | (3,522,832) | - | - | - |
| Operating Margin | (12323.9%) | (112238.9%) | (272.8%) | (278.5%) | (1144.7%) | (489.2%) | - | - | - |
| % EBITDA Margin | (12199.9%) | (111289.4%) | (269.5%) | (275.7%) | (1129.2%) | (480.0%) | - | - | - |
| NET Income (USD) | (1,360,993) | (1,482,362) | (728,093) | (1,491,191) | (2,160,561) | (2,450,500) | - | - | - |
| % Net Margin | (8248.4%) | (70588.7%) | (112.1%) | (163.3%) | (756.1%) | (340.3%) | - | - | - |
Vect-Horus S.A.S. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.